At a glance
| Zepbound | Saxenda | |
|---|---|---|
| Form | Weekly injection | Daily injection |
| How often | Once-weekly injection | Daily injection |
| Weight loss in trials | Up to 20.9% — SURMOUNT-1 (72 weeks) | Up to 8% — SCALE Obesity and Prediabetes (56 weeks) |
| FDA approved | 2023 | 2014 |
| Made by | Eli Lilly | Novo Nordisk |
| How it works | A single molecule that activates two hunger-regulating signals in the brain — GIP and GLP-1 (both natural hormones released after eating). | A GLP-1 analogue with a half-life of approximately 13 hours (requiring daily injection). |
| Monthly cost, self-pay | $299–$1,086/mowith the manufacturer savings programme; list ~$1,086 | $1,000–$1,349/mo |
| Most reported reaction | Nausea 31% (SURMOUNT-1) | Nausea 40% (SCALE Obesity and Prediabetes) |
Every figure in this table is read from the same trial and label records used everywhere else on this site.
Weight loss in each drug's main trial
No head-to-head trial has compared these two drugs.
SURMOUNT-1 (72 weeks)
SCALE Obesity and Prediabetes (56 weeks)
In clinical trials, participants taking tirzepatide lost on average up to 20.9% of their starting body weight, and participants taking liraglutide lost on average up to 8%. Those numbers come from two different studies: SURMOUNT-1 enrolled 2,539 adults with obesity or overweight with comorbidities, no type 2 diabetes over 72 weeks against placebo, while SCALE Obesity and Prediabetes enrolled 3,731 adults with obesity or overweight with comorbidities over 56 weeks against placebo. Who took part, how long each trial ran and what each drug was measured against all move the percentage, so the two figures are not a measured difference between the drugs.
Monthly cost, self-pay
The bar spans the range in each drug's price record — lowest listed price to highest.
with the manufacturer savings programme; list ~$1,086
Self-pay vials via LillyDirect from $299/month (2.5 mg) to $699/month (10–15 mg), per zepbound.lilly.com on 4 September 2026; list price ~$1,086/month; $25/month copay card for eligible commercial insurance.
Brand (Saxenda) ~$1,000–$1,349/month. Generic liraglutide is typically $135–$200 less than brand.
Self-pay prices are what the manufacturer or the pharmacy lists, not what most people end up paying. Zepbound: $299–$1,086/month. Saxenda: $1,000–$1,349/month. Insurance, dose and pharmacy all change both figures.
Side effects reported in the trials
Both trials reported 4 reactions in common. Each rate is the percentage of participants who reported it in the trial named beside it, so the two columns are not from the same study.
A rate is the share of trial participants who reported that reaction, not a prediction for any one person.
How they differ in practice
How you take it
- Zepbound — Once-weekly subcutaneous injection (2.5, 5, 7.5, 10, 12.5, 15 mg)
- Saxenda — Once-daily subcutaneous injection
Dose build-up
- Saxenda — 0.6 mg → 3.0 mg, escalated over 4 weeks
Where a drug is not listed here, its prescribing information sets out its own dose steps.
How soon it acts
- Zepbound — Noticeable appetite reduction typically within 4–8 weeks; significant weight loss by 12–16 weeks
- Saxenda — Effects visible within 4–8 weeks; maximum benefit typically by 56 weeks
Heart and metabolic findings
- Zepbound — Improvements in systolic/diastolic blood pressure, triglycerides, LDL, and HbA1c across SURMOUNT trials.
- Saxenda — The LEADER trial (type 2 diabetes) showed cardiovascular benefit.
As stated in each drug’s trial record — not a claim about which drug protects the heart more.
Other findings recorded
- Zepbound — Reduced progression to type 2 diabetes; improved sleep apnoea (SURMOUNT-OSA trial)
- Saxenda — Approved for adolescents aged 12 and over (SCALE teens programme); generic liraglutide now available (Teva, August 2025) — reducing out-of-pocket cost
If you stop taking it
- Zepbound — In SURMOUNT-4, participants who switched to placebo regained an average of 14.0% body weight over 52 weeks.
- Saxenda — Weight regain after stopping is expected, as with other GLP-1 drugs.
Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Clinical evidence — Tirzepatide and Liraglutide
No head-to-head trial has compared these two drugs.
- SURMOUNT-1 — Tirzepatide: 2,539 adults with obesity or overweight with comorbidities, no type 2 diabetes, 72 weeks. New England Journal of Medicine, 2022. View source ↗
- SCALE Obesity and Prediabetes — Liraglutide: 3,731 adults with obesity or overweight with comorbidities, 56 weeks. New England Journal of Medicine, 2015. View source ↗
- Zepbound (tirzepatide) — FDA prescribing information — DailyMed View source ↗
- Saxenda (liraglutide) — FDA prescribing information — DailyMed View source ↗
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: